美国成人白癜风患病率研究
该研究于2019年12月至2020年3月通过在线横断面调查,采用分层比例抽样从一般人群研究面板招募18至85岁美国成人,由3名皮肤科专家通过远程皮肤病学应用审核照片判定白癜风诊断。自报白癜风患病率为1.38%,专家裁定患病率(敏感性界限)为0.76%至1.11%;研究提示美国约40%的成人白癜风可能未被诊断,未来需进一步研究证实。
要点
- 自报白癜风患病率为1.38%,其中已诊断0.77%、未诊断0.61%。
- 专家裁定总体患病率(敏感性界限)为0.76%至1.11%。
- 研究提示美国约40%的成人白癜风可能未被诊断。
核心结论
- 本研究提示美国约40%的成人白癜风可能未被诊断,未来应开展研究以证实这些发现。
研究设计与样本
- 本研究为基于人群的横断面在线调查,于2019年12月至2020年3月实施,获取参与者自报白癜风状态。
- 采用分层比例抽样设计从一般人群研究面板招募18至85岁美国成人代表性样本,共纳入40888名合格成人参与者,平均(SD)年龄44.9(17.4)岁。
- 由3名皮肤科专家通过为本研究设计并测试的远程皮肤病学应用审核参与者上传的照片,对自报白癜风诊断进行裁定。
主要发现
- 自报白癜风患病率为1.38%(95%CI,1.26%-1.49%),其中已诊断0.77%(95%CI,0.68%-0.85%)、未诊断0.61%(95%CI,0.54%-0.69%)。
- 基于专家皮肤科医生对113张自报白癜风参与者照片的审核,临床裁定白癜风患病率(敏感性界限)为0.76%(0.76%-1.11%),其中已诊断0.46%(0.46%-0.61%)、未诊断0.29%(0.29%-0.50%)。
- 自报非节段性白癜风患病率为0.77%(95%CI,0.68%-0.85%),其中已诊断0.48%(95%CI,0.41%-0.55%)、未诊断0.29%(95%CI,0.23%-0.34%);临床裁定非节段性白癜风患病率(敏感性界限)为0.58%(0.57%-0.84%),其中已诊断0.37%(0.37%-0.49%)、未诊断0.21%(0.20%-0.36%)。
- 自报节段性白癜风患病率为0.61%(95%CI,0.53%-0.69%),其中已诊断0.28%(95%CI,0.23%-0.33%)、未诊断0.33%(95%CI,0.27%-0.38%);临床裁定节段性白癜风患病率(敏感性界限)为0.18%(0.18%-0.27%),其中已诊断0.09%(0.09%-0.12%)、未诊断0.08%(0.08%-0.15%)。
关键数值与推荐
- 自报白癜风总体患病率1.38%(95%CI,1.26%-1.49%)。
- 临床裁定白癜风总体患病率(敏感性界限)0.76%(0.76%-1.11%)。
- 自报非节段性白癜风患病率0.77%(95%CI,0.68%-0.85%),临床裁定非节段性白癜风患病率(敏感性界限)0.58%(0.57%-0.84%)。
- 自报节段性白癜风患病率0.61%(95%CI,0.53%-0.69%),临床裁定节段性白癜风患病率(敏感性界限)0.18%(0.18%-0.27%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 未来应开展研究以证实这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Vitiligo can have profound effects on patients and is often associated with other autoimmune comorbid conditions. It is important to understand the current prevalence of vitiligo, including diagnosed, undiagnosed, and subtypes (nonsegmental and segmental). OBJECTIVE: To estimate the point prevalence of vitiligo in the US. DESIGN, SETTING, AND PARTICIPANTS: For this population-based study of adults in the US, a cross-sectional online survey was administered between December 2019 and March 2020 to obtain participant self-reported vitiligo status. A representative sample of the US adult general population, aged 18 to 85 years, was recruited using a stratified proportional, sampling design from general population research panels. Additionally, 3 expert dermatologists adjudicated participants' self-reported vitiligo diagnosis by reviewing photographs uploaded by the participants using a teledermatology app designed and tested specifically for this study. MAIN OUTCOMES AND MEASURES: The main outcomes were the point prevalence estimates of overall vitiligo, as well as diagnosed, undiagnosed, nonsegmental, and segmental vitiligo. RESULTS: Among the 40 888 eligible adult participants, the mean (SD) age was 44.9 (17.4) years, 23 170 (56.7%) were female, 30 428 (74.4%) were White, and 4225 (10.3%) were of Hispanic, Latino, or Spanish origin. Self-reported vitiligo prevalence was 1.38% (95% CI, 1.26%-1.49%), with 0.77% (95% CI, 0.68%-0.85%) for diagnosed and 0.61% (95% CI, 0.54%-0.69%) for undiagnosed. Based on expert dermatologist review of 113 photographs of participants with self-reported vitiligo, clinician-adjudicated vitiligo prevalence (sensitivity bounds) was 0.76% (0.76%-1.11%), with 0.46% (0.46%-0.61%) for diagnosed and 0.29% (0.29%-0.50%) for undiagnosed. Self-reported nonsegmental vitiligo prevalence was 0.77% (95% CI, 0.68%-0.85%), with 0.48% (95% CI, 0.41%-0.55%) for diagnosed and 0.29% (95% CI, 0.23%-0.34%) for undiagnosed. Clinician-adjudicated nonsegmental vitiligo prevalence (sensitivity bounds) was 0.58% (0.57%-0.84%), with 0.37% (0.37%-0.49%) for diagnosed and 0.21% (0.20%-0.36%) for undiagnosed. Self-reported segmental vitiligo prevalence was 0.61% (95% CI, 0.53%-0.69%), with 0.28% (95% CI, 0.23%-0.33%) for diagnosed and 0.33% (95% CI, 0.27%-0.38%) for undiagnosed. Clinician-adjudicated segmental vitiligo prevalence (sensitivity bounds) was 0.18% (0.18%-0.27%), with 0.09% (0.09%-0.12%) for diagnosed and 0.08% (0.08%-0.15%) for undiagnosed. CONCLUSIONS AND RELEVANCE: Results of this survey study demonstrated that the current US population-based prevalence estimate of overall (diagnosed and undiagnosed combined) vitiligo in adults is between 0.76% (1.9 million cases in 2020) and 1.11% (2.8 million cases in 2020). Additionally, this study suggests that approximately 40% of adult vitiligo in the US may be undiagnosed. Future studies should be performed to confirm these findings.
引用
- Gandhi K, Ezzedine K, Anastassopoulos KP, et al. Prevalence of Vitiligo Among Adults in the United States. JAMA Dermatol. 2022. PMID: 34787670. doi:10.1001/jamadermatol.2021.4724
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。